Also found in: Medical.
ABECBacute bacterial exacerbations of chronic bronchitis
References in periodicals archive ?
Once-daily FACTIVE tablets offer short-course dosing (five days for ABECB and seven days for CAP) with no dosing adjustment requirements in the elderly, individuals with liver impairment or individuals with mild-to-moderate renal impairment.
In these studies, FACTIVE tablets demonstrated excellent clinical response rates at test-of-cure visit for CAP and ABECB as good as comparators including clarithromycin, levofloxacin, amoxicillin/clavulanate, ceftriaxone and oral cefuroxime.
23) A recent study by Kahn et al evaluated patients with ABECB.
The Anthonisen classification system helps to establish a diagnosis of ABECB.
6,2) More alarmingly, in a recent clinical study of younger, low-risk patients with ABECB, 35% of S.
With unproven safety profiles, are new agents the best choice for ABECB therapy?
In ABECB, variables associated with treatment failure may be loosely categorized as those relating to clinical issues (eg, infection with a resistant pathogen) or those resulting in increased costs.
Similar to ABS, variables associated with treatment failure in ABECB include recent antibiotic use and significant comorbidities, such as cardiac disease, which can increase the risk of treatment failure more than 2-fold.
4) Treatment with appropriate antibiotics significantly decreases bacterial airway burden, suggesting that appropriate antibiotic use can reduce the symptoms of ABECB and decrease the risk of progression to a more severe infection.
RELATED ARTICLE: Table 1: Criteria for Optimized Therapy of ABECB (6)
Atypical respiratory pathogens, most notably Chlamydophila (previously Chlamydia) pneumoniae, account for about 5% to 10% of organisms isolated from patients with ABECB.